Trial · NCT02737826
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients Who Tolerate Buprenorphine Initiation | 8 hours post dose | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants Who Achieve Opioid Cessation | 8 weeks after stabilization at Week 10 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Who Achieve Opioid Cessation Post-taper: 1 Month | 1 month post-taper | Only one person in the Gabapentin + Buprenorphine Taper Arm completed the 8 week study buprenorphine taper, making them eligible for analysis for this secondary outcome measure. Zero people in the Placebo + Buprenorphne Taper Arm completed the study buprenorphine taper. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Pain Self-report: Pain Catastrophizing Scale - Baseline | Baseline | One consented and randomized participant in the Placebo + Buprenorphine Taper Arm was erroneously randomized prior to buprenorphine induction, and dropped out of the study on the day of induction prior to receiving first buprenorphine dose (prior to eligibility for randomization). This participant is not included in this analysis. | units on a scale | MEAN |
| SECONDARY | Pain Laboratory Testing: Mechanical - Baseline | Baseline | One person was erroneously randomized to placebo before they were eligible for randomization and dropped out prior to induction, so they are not considered in this analysis. | grams per second | MEAN |
| SECONDARY | Mean Score of Current Opioid Measure (COMM) | Baseline | One person erroneously randomized to placebo before eligible for induction and who never completed buprenorphine induction not considered in this analysis. | units on a scale | MEAN |
| SECONDARY | Mean Score of PROMIS Physical Function Short Form (PROMIS SF 10) - RAW SCORE PH | baseline | This form was introduced after the first 2 participants had been randomized, so we only have this data for the 24 who were randomized after buprenorphine induction (vs n=26 for other outcome measures). One person was erroneously randomized prior to eligibility for randomization and was not included in calculations for these secondary outcomes. | units on a scale | MEAN |
| SECONDARY | Mean Score Pittsburgh Sleep Quality Index | baseline | One person erroneously randomized not included | units on a scale | MEAN |
| SECONDARY | Mean Score of Subjective Opioid Withdrawal Scale (SOWS) | baseline | units on a scale | MEAN | |
| SECONDARY | Number of Participants Who Achieved Opioid Cessation Post-taper - 3 Months | Post-taper - 3 months | One person in the Gabapentin + Buprenorphine Taper Arm completed the study buprenorphine taper and were eligible for analysis. Zero persons in the Placebo + Buprenorphine Taper Arm completed the study buprenoprhine taper and were eligible for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Achieved Opioid Cessation Post-taper - 6 Months | Post-taper - 6 months | One person in the Gabapentin + Buprenorphine Taper Arm completed the study buprenorphine taper, and zero persons in the Placebo + Buprenorphine Taper Arm completed the study buprenorphine taper. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Achieved Opioid Cessation Post-taper - 12 Months | Post-taper - 12 months | One person in the Gabapentin + Buprenorphine Taper Arm and Zero people in the Placebo + Buprenorphine Taper Arm completed the study buprenorphine taper. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Pain Laboratory Measures - Descending Noxious Inhibitory Control (DNIC) - Average, Baseline | Baseline | One person was erroneously randomized to placebo before eligible for randomization, and never completed buprenorphine induction, so they are not considered in this analysis. | percentage of change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02737826/outcomes